For Immediate Release

Chicago, IL – October 22, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Morgan Stanley (MS), Goldman Sachs (GS), St. Jude Medical, Inc. (STJ), Medtronic Inc. (MDT) and Boston Scientific Corporation (BSX).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s AnalystBlog:

Morgan Stanley Finally Profits

Morgan Stanley (MS) reported third-quarter 2009 income of $498 million this morning or 38 cents per share, compared with a loss of $159 million or $1.37 per share in the prior quarter and an income of $7.7 billion, or $7.38 per

...

St. Jude Medical, Inc. (STJ) today reported financial results for the third quarter of 2009 before the market opened. Earnings per share came in at 59 cents, compared to the Zacks Consensus Estimate of 58 cents and the year-ago earnings of 54 cents. Sales Net sales in the reported quarter increased 7% year over year to approximately $1.2 billion. Excluding an unfavorable foreign exchange translation (FX), net sales increased 10% year over year. Growth was witnessed across all the business segments. However, the company’s domestic revenues were below expectation primarily due to lack of purchase of cardiac rhythm management (CRM) devices by roughly 50 hospitals in the U.S. In terms of business segments: CRM revenues increased 2% year over year to $690 million. Growth was led by higher demand for both implantable cardioverter defibrillator (ICD) and pacemaker. ICD revenues increased 2% year over year to ...

St. Jude Medical, Inc. (STJ) received the CE (Conformite Europeenne) Mark of approval for the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device, known as the Brio neurostimulator. The device is used for treating symptoms of Parkinson’s disease. The Brio neurostimulator has 10-year battery longevity. This provides patients sustainable therapy for a longer period and maximizes the time between device replacement procedures. According to the European Parkinson’s Disease Association, Parkinson’s disease affects approximately 6.3 million people globally. People between 40 and 70 years of age, with an average age of 60, are mostly affected by this disease. The Brio neurostimulator approval enhances the breadth of St. Jude’s product offerings in the deep brain stimulation systems and increases the company’s top-line. St. Jude is a leading medical device manufacturer that designs, manufactures and distributes medical devices to treat cardiovascular and neurological conditions. St. Jude ...

St. Jude Medical, Inc. (STJ) received the CE (Conformite Europeenne) Mark approval for the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device, known as Brio neurostimulator. The device is used for treating symptoms of Parkinson’s disease. The Brio neurostimulator has 10-year battery longevity. This provides patients sustainable therapy for a longer period and maximizes the time between device replacement procedures. According to the European Parkinson’s Disease Association, Parkinson’s disease affects approximately 6.3 million people globally. People between 40 and 70 years of age, with an average age of 60, are mostly affected by this disease. The Brio neurostimulator approval enhances the breadth of St. Jude’s product offerings in the deep brain stimulation systems and increases the company’s top-line. St. Jude is a leading medical device manufacturer that designs, manufactures and distributes medical devices to treat cardiovascular and neurological conditions. St. Jude has also ...

St. Jude Medical, Inc. (STJ) set a new milestone by introducing pacemaker devices in the U.S. with automatic test results and complete diagnostics facilities that can be accessed remotely via wireless communication. Yesterday, the company received the U.S. Food and Drug Administration (FDA) approval for these pacemakers - Accent RF and Anthem RF CRT.

In addition, St. Jude has received both the FDA and European CE Mark approval for the technology used in these pacemakers, version 4.0 of the Merlin.net Patient Care Network (PCN).

Accent and Anthem pacemakers use Radio Frequency (RF) telemetry that enables secure and smooth flow of data between the pacemaker and the clinician thereby enhancing the patient care. These devices use Merlin.net PCN technology that captures and records information about the performance of the pacemaker and the patient heart rhythm and subsequently send the data to a hospital’s Electronic Health Records system.

The new approval will add to

...